Waters L, Assoumou L, Gonzalez-Cordon A, Rusconi S, et al. Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial. Clin Infect Dis 2022 Oct 19. pii: 6763268. doi: 10.1093.
PMID: 36259527